Has Your Melanoma Stopped Responding to Immunotherapy?
For advanced melanoma that has progressed after PD-1 therapy (Keytruda, Opdivo, etc.), GC101 TIL therapy in China offers a treatment option with 42% response rate and zero treatment-related deaths in the Phase II trial.
Melanoma in Asian Populations
Unlike in Western countries where cutaneous melanoma accounts for over 90% of cases, melanoma in China and other Asian populations has a very different distribution.
Why Asian Melanoma Patients Face Higher Challenges
Acral and mucosal melanomas have lower tumor mutational burden (TMB) than cutaneous melanoma, making them less visible to PD-1 checkpoint inhibitors. China accounts for only 2.7% of global melanoma cases but 9.2% of global melanoma deaths — mortality is 3.4× the global average, largely due to more aggressive subtypes.
When Standard Treatments Fail
The standard pathway — PD-1 inhibitors → chemotherapy → limited options — is especially inadequate for acral and mucosal subtypes. TIL therapy addresses this differently: rather than broadly activating the immune system, it amplifies existing tumor-specific T cells that already recognize the patient's unique tumor antigens.
GC101 Clinical Results for Melanoma
The MIZAR-003 Phase II randomized controlled trial, led by Prof. Jun Guo (郭军) at Peking University Cancer Hospital, is the largest TIL therapy study in melanoma reported to date with a focus on Asian-predominant subtypes.
ASCO 2026 Late-Breaking Abstract (LBA 9509): GC101 met its primary endpoint with a 42% ORR and 4.3-month median PFS (HR 0.43, p=0.0002 vs chemotherapy). Zero treatment-related deaths were observed. Study enrolled 98 patients, 81.8% with acral or mucosal melanoma. Full report →
Phase II RCT: MIZAR-003 Pivotal Results
| Endpoint | GC101 TIL (n=49) | Chemotherapy (n=49) |
|---|---|---|
| Objective Response Rate (ORR) | 42.0% | 6.1% |
| Median Progression-Free Survival (PFS) | 4.3 months | 1.6 months |
| Hazard Ratio (95% CI) | 0.43 [0.28–0.65], p=0.0002 | |
| 6-month PFS rate | 36.0% | 8.0% |
| Disease Control Rate (DCR) | 72.0% | 24.5% |
| Complete Response (CR) | 8.2% | 0% |
| Treatment-related deaths | 0 | 0 |
| As reported at ASCO 2026, LBA 9509. Presented by Dr. Lu Si; PI Prof. Jun Guo. Single-trial analysis — confirmatory studies needed. | ||
Phase I Results: Safety and Efficacy Established
In the completed Phase I trial, GC101 demonstrated a 34.8% ORR and 78.3% DCR across multiple solid tumors including melanoma. Three patients achieved complete responses — the longest disease-free survival exceeding two years and ongoing at data publication.
Important distinction: Unlike Iovance's lifileucel trial (enrolled predominantly cutaneous melanoma), MIZAR-003 specifically includes acral and mucosal subtypes. Despite a more challenging patient population, GC101 demonstrated comparable or superior efficacy.
Safety Profile
The most significant safety advantage of GC101 is the elimination of lymphodepletion conditioning chemotherapy. Traditional TIL protocols require high-dose chemotherapy (cyclophosphamide + fludarabine) causing severe bone marrow suppression and infections. With GC101, the TIL infusion can be administered in a general hospital ward. The most common adverse events — fever, rash, chills — are mild to moderate and resolve with standard symptomatic treatment. Zero treatment-related deaths have been observed across all clinical trials to date.
Real Patient Outcomes
These cases from the GC101 clinical program illustrate the potential of TIL therapy in advanced melanoma patients who had exhausted all other treatment options.
Acral Melanoma — Complete Response
A female patient in her 50s with acral melanoma on the left elbow and lymph node metastases. After all standard therapies failed to control the disease, she received a single GC101 infusion. At 6 weeks, imaging showed significant tumor shrinkage. By 8 months, imaging confirmed complete metabolic response — no active disease. She returned to normal work, with ongoing disease-free status beyond 2 years.
High Tumor Burden Acral Melanoma — Partial Response
A female patient with acral melanoma on the right foot (2018) with recurrence in 2024 including lung, pleural, and peritoneal metastases. The primary foot lesion grew to ~9 cm despite two lines of therapy including PD-1 and dual immunotherapy. After GC101 infusion, 18-week evaluation showed partial response: lung lesion reduced by 47.4%, peritoneal lesion by 31.7%, foot lesion by 36.0%. Only mild immune-related symptoms were observed.
Eligibility for TIL Therapy
- Confirmed diagnosis: Histologically confirmed malignant melanoma (any subtype including acral, mucosal, cutaneous)
- Stage: Unresectable stage III or stage IV disease
- Treatment history: Progression on or intolerance to PD-1/PD-L1 therapy
- Measurable disease: At least one safely accessible tumor lesion (min 1-2 cm)
- Performance status: ECOG 0-1 and adequate organ function
Note on subtypes: MIZAR-003 includes acral and mucosal subtypes — unlike US-approved lifileucel which enrolled predominantly cutaneous melanoma. If you have acral or mucosal melanoma that has failed PD-1 therapy, GC101 may be one of the few effective options available.
The Treatment Journey
Step 1: Free Consultation
Submit your medical records for review. CancerPath assesses eligibility at no cost.
Step 2: Tissue Collection in Shanghai (2-3 days)
A small tumor tissue sample is collected via minimally invasive procedure.
Step 3: Cell Manufacturing (4-6 weeks)
TIL cells are expanded at Juncell's GMP facility using the DeepTIL platform.
Step 4: Cell Infusion in Hainan (3 days)
Return to Hainan Boao Lecheng medical zone for the infusion procedure.
Step 5: Ongoing Follow-Up
CancerPath coordinates remote imaging follow-up and ongoing support.
GC101 vs. Standard TIL Therapy
| Factor | GC101 (China) | Iovance Lifileucel (US) |
|---|---|---|
| Approved subtypes | All incl. acral, mucosal | Cutaneous primarily |
| Overall ORR | 42% (Phase II RCT) | 31-36% |
| Lymphodepletion | No | Yes — high-dose chemo |
| IL-2 support | No | Yes — high-dose IL-2 |
| ICU stay | No | Often required |
| Estimated cost | ~$110,000 | $515,000+ |
Frequently Asked Questions About TIL Therapy for Melanoma
What makes acral melanoma different?
Acral melanoma occurs on non-sun-exposed areas — palms, soles, under nails. These subtypes have lower tumor mutational burden, making them less visible to PD-1 checkpoint inhibitors. This is why standard immunotherapy is less effective for these subtypes and why TIL therapy, which uses your own tumor-fighting cells, can be a better option.
How effective is TIL therapy for advanced melanoma?
In the MIZAR-003 Phase II randomized trial presented at ASCO 2026, GC101 achieved 42% objective response rate vs 6.1% for chemotherapy. Median progression-free survival was 4.3 months vs 1.6 months (HR 0.43, p=0.0002). 81.8% of enrolled patients had acral or mucosal subtypes.
How much does TIL therapy cost in China vs the US?
The US-approved TIL therapy Amtagvi is priced at approximately $515,000. In China, GC101 clinical trial participation is free, and out-of-pocket costs if accessing outside a trial are approximately $50,000-$100,000 — including surgery, lab processing, hospitalization, and supportive care.
Is TIL therapy safe for melanoma patients?
GC101's safety profile is significantly better than conventional TIL therapy. It requires no lymphodepletion chemotherapy, no high-dose IL-2 injections, and no ICU stay. Zero treatment-related deaths have been observed across all GC101 trials. The most common side effects are mild to moderate fever, chills, and rash that resolve with standard treatment.
Can I receive TIL therapy in China as a foreign patient?
Yes. Foreign nationals can legally enroll in Chinese clinical trials. Juncell's clinical coordinators handle international patients in English. You'll need a valid passport, medical records, and be willing to travel to China for two trips — approximately 5-6 days for biopsy and 2-3 weeks for infusion.
Who is the principal investigator for the melanoma trial?
MIZAR-003 is led by Prof. Jun Guo (郭军) at Peking University Cancer Hospital. Prof. Guo is Vice President of CSCO, Chairman of the CSCO Melanoma Expert Committee, and Vice President (Asia) of the Melanoma World Society.
Explore TIL Therapy for Your Melanoma
If you have advanced melanoma that has progressed after PD-1 therapy, GC101 TIL therapy may offer a path forward. Request a free eligibility assessment today.
Email clinicaltrials@juncell.com →